Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC announces that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP (2.5mg/6.25mg, 5mg/6.25mg, and 10mg/6.25mg), a generic version of Ziac®* tablets (2.5mg/6.25mg, 5mg/6.25mg, and 10mg/6.25mg). Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP are indicated in the management of hypertension. Edenbridge intends to begin shipping this newly approved product shortly. For more information please contact the Company directly at info@dexcelpharmausa.com.
Bisoprolol Fumarate and Hydrochlorothiazide Tablets Approval
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.